报告时间：2023年9月18日

               下午3:00-4:00

报告地点：中国人民大学明德主楼1016

                腾讯会议（会议ID：981-923-124）

报告嘉宾：付博

报告主题：从数据科学在医药临床开发策略的思考到制药行业统计师

报告摘要

从数据科学在医药临床开发策略的思考到制药行业统计师

Pharmaceutical industry has been witnessed with growing emphasize recent years in China， reflected in the accelerated evolution of innovative therapies’ development and marketing authorization, and the surging number of regulations and guidance from the health agency. This talk will portrait the promising career of statistics within the pharmaceutical industry. Statistical considerations that impact the development strategy of COVID-19 product is used to lead through the journey of the influential thinking in clinical development and pivotal role of statistics in driving successful drug development. The talk will also delve into the regulatory policy development in China pertaining to medical product development and the ICH guidance to shape the industry practices. Lastly, we will shed light and have you comprehensive understanding on the quantitative science roles in the pharmaceutical industry.

作者简介

付博，博士，安斯泰来中国统计与真实世界数据科学部门负责人。付博博士曾在默沙东，艾伯维，赛诺菲等跨国药企作为部门负责人或项目负责人致力于创新医疗药物研发，在疫苗，肿瘤，感染，免疫，基因和细胞疗法领域均有成功的药物和疫苗在世界主要国家和地区上市。付博博士的研究领域主要在适应性临床实验设计，药品获益风险评估，真实世界数据，发表五十余篇论文和专业书籍章节；付博博士作为IFPMA专家代表在ICH国际专家组进行临床试验指导原则修订和撰写；参与多个国家国际专业组织的委员会，包括中国外商投资企业协会药品研制和开发工作委员会；泛华统计协会科学委员会，美国统计协会和监管行业统计研讨会运营委员会，美国华人科学家工程师专业人士协会指导委员会等。